CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- PositionOperating margin is 50.5%, higher than 95% of its Biotechnology peers (median -34.2%)
- FinancialsAltman Z-Score -0.72: distress zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
453.38MUSDvs all stocks (USD)
Revenue (TTM)
57.94MUSDvs all stocks (USD)
Profit Margin
-260.92%vs Biotechnology peers
Beta
-0.3140xvs all stocks
52-Week Change
37.68%vs all stocks
Market Capitalization
453.38MUSDvs all stocks (USD)
Enterprise Value
131.57MUSDvs all stocks (USD)
Forward P/E
-6.61xvs Biotechnology peers
Price to Sales (TTM)
7.82xvs Biotechnology peers
Price to Book (MRQ)
1.47xvs Biotechnology peers
Enterprise to Revenue
2.27xvs Biotechnology peers
Enterprise to EBITDA
-1.43xvs Biotechnology peers
Profit Margin
-260.92%vs Biotechnology peers
Operating Margin
50.49%vs Biotechnology peers
Return on Assets (TTM)
-13.78%vs Biotechnology peers
Return on Equity (TTM)
-40.30%vs Biotechnology peers
Revenue (TTM)
57.94MUSDvs all stocks (USD)
Revenue per Share (TTM)
1.08USDUpdated Jul 19, 2026Quarterly Revenue Growth
1706.40%vs Biotechnology peers
Gross Profit (TTM)
-38.73MUSDvs all stocks (USD)
EBITDA (TTM)
-92.33MUSDvs all stocks (USD)
Net Income (TTM)
-151.18MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
1706.36%vs Biotechnology peers
Operating Cash Flow (TTM)
-81.34MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-31.58MUSDvs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Revenue
9.68MUSDFY2025 · Dec 31, 2025Operating Income
-184.56MUSDvs all stocks (USD)
Pre-tax Income
-200.83MUSDFY2025 · Dec 31, 2025Income Tax Expense
43.26MUSDFY2025 · Dec 31, 2025Net Income
-244.09MUSDFY2025 · Dec 31, 2025EBIT
-184.56MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-153.26MUSDFY2025 · Dec 31, 2025Research & Development
134.85MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
59.39MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
14.14MUSDFY2025 · Dec 31, 2025EPS (Basic)
-4.53USDFY2025 · Dec 31, 2025EPS (Diluted)
-4.53USDFY2025 · Dec 31, 2025Basic Shares Outstanding
53.83MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
53.83MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-244.09MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-174.31MUSDFY2025 · Dec 31, 2025Free Cash Flow
-174.45MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
308.39MUSDFY2025 · Dec 31, 2025Income Tax Paid
931.00KUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-244.09MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
895.00KUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
43.24MUSDFY2025 · Dec 31, 2025Stock-based Compensation
37.64MUSDFY2025 · Dec 31, 2025Other Non-cash Items
2.81MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
0.00USDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-15.78MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
975.00KUSDFY2025 · Dec 31, 2025Capital Expenditures
-138.00KUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-138.00KUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-139.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-139.00KUSDFY2025 · Dec 31, 2025Shares Outstanding
53.08MSharesUpdated Jul 19, 2026Float Shares
36.68MSharesUpdated Jul 19, 2026Shares Short
8.37MSharesUpdated Jul 19, 2026Short Ratio
13.32daysvs all stocks
Short % of Shares Outstanding
19.18%vs all stocks
% Held by Insiders
20.18%vs all stocks
% Held by Institutions
90.76%vs all stocks
Total Cash (MRQ)
329.46MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
6.29USDUpdated Jul 19, 2026Total Debt (MRQ)
7.65MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0245xvs Biotechnology peers
Current Ratio (MRQ)
10.43xvs Biotechnology peers
Book Value per Share (MRQ)
5.89USDUpdated Jul 19, 2026Total Assets
326.80MUSDvs all stocks (USD)
Total Current Assets
315.19MUSDFY2025 · Dec 31, 2025Total Liabilities
46.33MUSDFY2025 · Dec 31, 2025Total Non-current Assets
11.61MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
5.49MUSDFY2025 · Dec 31, 2025Total Current Liabilities
40.84MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
307.53MUSDFY2025 · Dec 31, 2025Accounts Payable
5.88MUSDFY2025 · Dec 31, 2025Short-term Debt
2.89MUSDFY2025 · Dec 31, 2025Deferred Revenue
2.66MUSDFY2025 · Dec 31, 2025Other Current Liabilities
13.74MUSDFY2025 · Dec 31, 2025Long-term Debt
5.49MUSDFY2025 · Dec 31, 2025Common Stock (Book)
538.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-1.35BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
280.47MUSDvs all stocks (USD)
52-Week Low
6.24USDUpdated Jul 19, 202652-Week High
11.80USDUpdated Jul 19, 202652-Week Change
37.68%vs all stocks
Beta
-0.3140xvs all stocks
50-Day MA
9.33USDUpdated Jul 19, 2026200-Day MA
9.71USDUpdated Jul 19, 2026Avg 10-Day Volume
522.93KSharesUpdated Jul 19, 2026Avg 30-Day Volume
594.46KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-2.81USDUpdated Jul 19, 2026Other Income / Expense
-30.41MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is 50.5%, higher than 95% of its Biotechnology peers (median -34.2%)Significant
Operating margin: 0.50Industry median: -0.34Industry P95: 0.41Peers compared: 261
Structural Tensions
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 10.43Altman Z-Score: -0.72
Financial Health
Altman Z-Score -0.72: distress zoneCritical
Altman Z-Score: -0.72
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Allergy Therapeutics plc
Tier 1ProductionApproval-Gated PipelineRule
Kyverna Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Ever Supreme Bio Technology Co., Ltd
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhejiang Shouxiangu Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
ClearPoint Neuro Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Nanjing Medlander Medical Inc.
Tier 1ProductionApproval-Gated PipelineRule
Guizhou Yibai Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Editas Medicine Inc.
Tier 1ProductionApproval-Gated PipelineRule
Cybin Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Honz Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow